Infertility, FemaleDEFETOSENCT03349905
Deferred Versus Fresh Embryo Transfers
A study testing fresh transfer and Deferred-frozen embryo transfer in people with Infertility, Female, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Infertility, Female
- What is being tested?
- fresh transfer and Deferred-frozen embryo transfer
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 237 participants
- Where
- 1 siteFrance
- Study dates
- 24 Sep 2018to 31 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women [18 - 40[years of age (according to date of birth at time of informed consent) who are eligible for ovarian stimulation and ART treatment, including intracytoplasmic sperm injection (ICSI)
- Absence of anatomical abnormalities of the reproductive tract that would interfere with implantation or pregnancy
- Absence of any medical condition in which pregnancy is contraindicated
- Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). Intracytoplasmic sperm injection (ICSI) will be allowed during this trial
- Body mass index 18 to 35 kg/m2, inclusive
- Able to understand the study
- Affiliation with a social security scheme
- Dated and signed inform consent
Who cannot join
- Altered ovarian reserve (Day3: FSH >12 UI/l; AMH<1,0 ng/ml; AFC<8)
- History or presence of tumours of the hypothalamus or pituitary gland
- Presence of non isolated uni- or bilateral hydrosalpinx
- Abnormal gynaecological bleeding of undetermined origin
- Contraindication to being pregnant and/or carrying a pregnancy to term
- Known infection with human immunodeficiency virus, active hepatitis B or C virus in the female or male partner
Show all 17Show fewer
- History or presence of ovarian, uterine or mammary cancer
- Known allergy or hypersensitivity to human gonadotropin preparations or to compounds that are structurally similar to any of the other medications administered during the trial
- Substance abuse that would interfere with trial conduct, as determined by the investigator
- Use of testicular or epididymal sperm
- Pregnant patient, nursing patient
- Participation in another ART clinical trial within the past 30 days
- Women who have risk to develop severe ovarian hyperstimulation syndrome (OHSS) during controlled ovarian stimulation (COS) defined as ≥ 18 follicles measuring 10 - 14 mm on the day of triggering
- Women with less than 3 follicles ≥ 15 mm on the triggering day or the day before the triggering
- Women with premature progesterone elevation during COS ( ≥1.5 ng/ml)
- Women with uterine polyps diagnosed during COS
- Participation with another interventional study involving human subjects
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Trial of Deferred Versus Fresh Embryo Transfers in Infertile Women Undergoing IVF-ICSI
Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Previous reports suggest that pregnancy rates are increased following deferred frozen embryo transfers. In addition as compared to fresh embryo transfers, frozen embryo transfers seem to be associated with less affected perinatal outcomes, in particular lower risk of preterm birth, small for gestational age and caesarean section. Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, whether differing embryo transfers could restore optimal ER leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfers, is actually still under investigation.
Read the detailed description
Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Recently, technical improvements in vitrification make frozen embryo transfers (FETs) a safe and feasible alternative to fresh embryo transfer (Evans et al., 2014). In case of FET the absence of COS avoid the alteration of endometrial receptivity. Previous reports suggest that pregnancy rates are increased and perinatal outcomes are less affected following FET (Evans et al., 2014). In fact previous studies plead for increased risk of preterm birth, small for gestational age, caesarean section after fresh embryo transfer as compared to frozen embryo transfer (Maheshwari et al., 2012). Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, one of the main questions, in the management of infertile women, is to know whether differing embryo transfers could restore optimal endometrial receptivity leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfer. This question is actually debated in the literature in many different reviews (Blockeel et al., 2016; Cedars, 2016; Engmann et al., 2016; Evans et al., 2014; Roque, 2015). However even if the scientific rationale is in favour of increased pregnancy rates after differed FET, compelling clinical evidence is still lacking and most of the current evidence is based on retrospective and uncontrolled studies. Currently the best evidence come from a very recent randomized control trial of fresh versus frozen embryo transfers in a specific population of polycystic ovary syndrome affected women (Chen et al., 2016). The authors failed to show any difference in pregnancy rate after fresh versus frozen embryo transfers but they found higher rate of miscarriages after fresh embryo transfers and in consequence a slight but significant decrease in live birth after fresh as compared to frozen embryo transfers (Chen et al., 2016). However whether these results, coming from a specific population of polycystic ovary syndrome affected women, may be generalizable is actually still unknown. Furthermore some evidence come from a meta-analysis, including 3 randomized studies. The conclusions of this meta-analysis are that IVF outcomes may be improved by performing FET compared with fresh embryo transfer probably through an improvement of endometrial receptivity (Roque et al., 2013). Nevertheless, this meta-analysis should be interpreted with caution. One of the included studies had been retracted from literature because of methodological problem (Aflatoonian et al., 2010). Therefore, this meta-analysis banking on a retracted study seems no more valid and therefore its conclusions remained uncertain. Even in absence of solid clinical studies and even in absence of valid recommendations, some authors conclude that IVF outcomes can be improved using the freeze-all policy with differed FET (Roque et al., 2015). In addition they recommend that further randomized clinical trials are needed to confirm the advantage of this strategy and determine the population for which it would be most beneficial. This last point seems crucial as ART procedures (IVF-ICSI) encompass a mixture of different fertility problem more or less sensible to the effects of COS on endometrial receptivity. Among the different causes of infertility, endometriosis is quite common and up to 20 % of women undergoing ART have associated endometriosis (Kawwass et al., 2015; Kuivasaari-Pirinen et al., 2012; Senapati et al., 2016). In addition endometriosis is characterized by impaired endometrial receptivity, contributing to the mechanisms by which endometriosis interfere with fecundity (de Ziegler et al., 2010). Estimated prevalence of endometriosis range from 2 to 10% of women of reproductive age, to 50% of infertile women (Eskenazi and Warner, 1997; Meuleman et al., 2009). Reverting to ART in case of endometriosis related infertility remain a solid option. However recent meta-analysis evocates decreased live birth rate in case of severe endometriosis as compared to disease free women (Hamdan et al., 2015). In addition endometriosis may be associated to adverse obstetrical outcomes (Leone Roberti Maggiore et al., 2016). Thus, given the existence of altered endometrial receptivity in endometriosis, and diminished ART outcomes, it is actually also debated whether deferring embryo transfers could restore optimal endometrial receptivity leading to higher live birth rate and reduced obstetrical risk in endometriosis affected women.
- Conditions
- Infertility, Female
- Being tested
- fresh transfer, Deferred-frozen embryo transfer
- Keywords
- Freeze all, IVF, deferred embryo transfer, endometriosis
- Medical subject headings
- Infertility, Female, Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fresh transferProcedure or surgery
Women randomized in the non experimental group will have:
- Antagonist stimulation protocol
- Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)
- All of their embryo kept in prolonged culture
- A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)
- Supernumerary blastocysts cryopreserved
Deferred-frozen embryo transferProcedure or surgery
Women randomized in the experimental group will have:
- Antagonist stimulation protocol
- Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)
- All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.
- A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation
| Study group | Role | What they receive |
|---|---|---|
| Fresh transfer | Active comparator | Women randomized in the non experimental group will have:
* Antagonist stimulation protocol
* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)
* All of their embryo kept in prolonged culture
* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)
* Supernumerary blastocysts cryopreserved Receives: Procedure: fresh transfer |
| Deferred-frozen embryo transfer | Experimental | Women randomized in the experimental group will have:
* Antagonist stimulation protocol
* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)
* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.
* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation Receives: Procedure: Deferred-frozen embryo transfer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Live birth rates
The cut-off of 35 weeks postmenstrual age is to ensure the health and well being of the newborns babies.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Secondary outcomes (19)
Miscarriage
Miscarriage is defined as an intrauterine clinical pregnancy that occurs before 20 completed weeks postmenstrual age (18 weeks post fertilization). Clinical pregnancy is defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Preterm birth
Preterm birth is defined as a live birth or stillbirth that takes place after at least 20 but before 37 completed weeks of postmenstrual age.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Preterm rupture of membranes
s defined as rupture of the foetal membranes occurring before labour and prior to 37 weeks of postmenstrual age.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Pre-eclampsia
is defined as gestational hypertension (Blood pressure ≥ 14 mm Hg systolic or ≥ 9 mm Hg diastolic, measured on two occasions at least four hours apart) associated with proteinuria ≥ 0.3 grams (300 mg) or more of protein in a 24-hour urine sample.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Placenta praevia
is defined by the presence of lower edge of the placenta < 50 mm behind the internal cervical os as diagnosed during the obstetrical ultrasound during the third trimester of the pregnancy. We also defined as placenta praevia when placenta partially or completely covers the internal cervical.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Live birth rates in Endometriosis related infertility
Analysis of live birth among women with endometriosis related infertility
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Number of oocytes retrieved
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of MII oocytes
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of embryo
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of blastocyst
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of transferred blastocyst
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The cancellation rate
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The rate of started pregnancy
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The rate of pregnancy confirmed by the Echography (cardiac activity)
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Started pregnancy defined by a rate of HCG>100
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Rate of multiple pregnancy
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Implantation rate
defined as the number of gestational sacs seen via transvaginal ultrasonography 4-5 weeks after embryo transfer, per number of embryos transferred
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Cryopreservation thaw rate
defined as percentage of vitrified blastocysts which survive warming.
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The incremental cost effectiveness ratio
using live birth rate as the effectiveness endpoint, after 35 weeks
Measured: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Nov 2017
- Study start24 Sep 2018
- Primary completion19 Jan 2022
- Study completion31 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Infertility, FemaleStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Responsible party
- Sponsor
- Investigators
- Khaled POCATE, PhD, Study chair, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03349905
- Sponsor's protocol ID
- K160918J
- Other IDs
- AOM160313
- Acronym
- DEFETOSE
- Status last verified
- Mar 2026
- First submitted
- 17 Nov 2017
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zaat T, Zagers M, Mol F, Goddijn M, van Wely M, Mastenbroek S. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD011184. doi: 10.1002/14651858.CD011184.pub3.
PubMed 33539543
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Trial of Deferred Versus Fresh Embryo Transfers in Infertile Women Undergoing IVF-ICSI
- ClinicalTrials.gov ID
- NCT03349905
- Acronym / sponsor ID
- DEFETOSE / K160918J
- Conditions
- Infertility, Female
- Keywords
- Freeze all, IVF, deferred embryo transfer, endometriosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Study start
- 24 Sep 2018 (actual)
- Primary completion
- 19 Jan 2022 (actual)
- Study completion
- 31 Mar 2022 (actual)
- First posted
- 22 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Previous reports suggest that pregnancy rates are increased following deferred frozen embryo transfers. In addition as compared to fresh embryo transfers, frozen embryo transfers seem to be associated with less affected perinatal outcomes, in particular lower risk of preterm birth, small for gestational age and caesarean section. Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, whether differing embryo transfers could restore optimal ER leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfers, is actually still under investigation.
Detailed description
Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Recently, technical improvements in vitrification make frozen embryo transfers (FETs) a safe and feasible alternative to fresh embryo transfer (Evans et al., 2014). In case of FET the absence of COS avoid the alteration of endometrial receptivity. Previous reports suggest that pregnancy rates are increased and perinatal outcomes are less affected following FET (Evans et al., 2014). In fact previous studies plead for increased risk of preterm birth, small for gestational age, caesarean section after fresh embryo transfer as compared to frozen embryo transfer (Maheshwari et al., 2012). Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, one of the main questions, in the management of infertile women, is to know whether differing embryo transfers could restore optimal endometrial receptivity leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfer. This question is actually debated in the literature in many different reviews (Blockeel et al., 2016; Cedars, 2016; Engmann et al., 2016; Evans et al., 2014; Roque, 2015). However even if the scientific rationale is in favour of increased pregnancy rates after differed FET, compelling clinical evidence is still lacking and most of the current evidence is based on retrospective and uncontrolled studies. Currently the best evidence come from a very recent randomized control trial of fresh versus frozen embryo transfers in a specific population of polycystic ovary syndrome affected women (Chen et al., 2016). The authors failed to show any difference in pregnancy rate after fresh versus frozen embryo transfers but they found higher rate of miscarriages after fresh embryo transfers and in consequence a slight but significant decrease in live birth after fresh as compared to frozen embryo transfers (Chen et al., 2016). However whether these results, coming from a specific population of polycystic ovary syndrome affected women, may be generalizable is actually still unknown. Furthermore some evidence come from a meta-analysis, including 3 randomized studies. The conclusions of this meta-analysis are that IVF outcomes may be improved by performing FET compared with fresh embryo transfer probably through an improvement of endometrial receptivity (Roque et al., 2013). Nevertheless, this meta-analysis should be interpreted with caution. One of the included studies had been retracted from literature because of methodological problem (Aflatoonian et al., 2010). Therefore, this meta-analysis banking on a retracted study seems no more valid and therefore its conclusions remained uncertain. Even in absence of solid clinical studies and even in absence of valid recommendations, some authors conclude that IVF outcomes can be improved using the freeze-all policy with differed FET (Roque et al., 2015). In addition they recommend that further randomized clinical trials are needed to confirm the advantage of this strategy and determine the population for which it would be most beneficial. This last point seems crucial as ART procedures (IVF-ICSI) encompass a mixture of different fertility problem more or less sensible to the effects of COS on endometrial receptivity. Among the different causes of infertility, endometriosis is quite common and up to 20 % of women undergoing ART have associated endometriosis (Kawwass et al., 2015; Kuivasaari-Pirinen et al., 2012; Senapati et al., 2016). In addition endometriosis is characterized by impaired endometrial receptivity, contributing to the mechanisms by which endometriosis interfere with fecundity (de Ziegler et al., 2010). Estimated prevalence of endometriosis range from 2 to 10% of women of reproductive age, to 50% of infertile women (Eskenazi and Warner, 1997; Meuleman et al., 2009). Reverting to ART in case of endometriosis related infertility remain a solid option. However recent meta-analysis evocates decreased live birth rate in case of severe endometriosis as compared to disease free women (Hamdan et al., 2015). In addition endometriosis may be associated to adverse obstetrical outcomes (Leone Roberti Maggiore et al., 2016). Thus, given the existence of altered endometrial receptivity in endometriosis, and diminished ART outcomes, it is actually also debated whether deferring embryo transfers could restore optimal endometrial receptivity leading to higher live birth rate and reduced obstetrical risk in endometriosis affected women.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fresh transfer | Active comparator | Procedure: fresh transferWomen randomized in the non experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France) * All of their embryo kept in prolonged culture * A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage) * Supernumerary blastocysts cryopreserved |
| Deferred-frozen embryo transfer | Experimental | Procedure: Deferred-frozen embryo transferWomen randomized in the experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France) * All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture. * A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Women [18 - 40[years of age (according to date of birth at time of informed consent) who are eligible for ovarian stimulation and ART treatment, including intracytoplasmic sperm injection (ICSI)
- Absence of anatomical abnormalities of the reproductive tract that would interfere with implantation or pregnancy
- Absence of any medical condition in which pregnancy is contraindicated
- Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). Intracytoplasmic sperm injection (ICSI) will be allowed during this trial
- Body mass index 18 to 35 kg/m2, inclusive
Key exclusion criteria (17 listed)
- Altered ovarian reserve (Day3: FSH >12 UI/l; AMH<1,0 ng/ml; AFC<8)
- History or presence of tumours of the hypothalamus or pituitary gland
- Presence of non isolated uni- or bilateral hydrosalpinx
- Abnormal gynaecological bleeding of undetermined origin
- Contraindication to being pregnant and/or carrying a pregnancy to term
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fresh transferWomen randomized in the non experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France) * All of their embryo kept in prolonged culture * A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage) * Supernumerary blastocysts cryopreserved | Procedure or surgery | Fresh transfer |
| Deferred-frozen embryo transferWomen randomized in the experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France) * All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture. * A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation | Procedure or surgery | Deferred-frozen embryo transfer |
Primary outcome
Live birth rates
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The cut-off of 35 weeks postmenstrual age is to ensure the health and well being of the newborns babies.
19 secondary outcomes
Miscarriage
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Preterm birth
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Preterm rupture of membranes
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Pre-eclampsia
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Placenta praevia
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Live birth rates in Endometriosis related infertility
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer a
Number of oocytes retrieved
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of MII oocytes
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of embryo
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of blastocyst
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Number of transferred blastocyst
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The cancellation rate
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The rate of started pregnancy
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The rate of pregnancy confirmed by the Echography (cardiac activity)
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Started pregnancy defined by a rate of HCG>100
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Rate of multiple pregnancy
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Implantation rate
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Cryopreservation thaw rate
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
The incremental cost effectiveness ratio
Time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- Derived from this study: PubMed 33539543Zaat T, Zagers M, Mol F, Goddijn M, van Wely M, Mastenbroek S. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD011184. doi: 10.1002/14651858.CD011184.pub3.
Related trials for Infertility, Female
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Khaled POCATE, PhD study chair
Assistance Publique - Hôpitaux de Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing fresh transfer and Deferred-frozen embryo transfer in people with Infertility, Female, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Live birth rates (time frame: ≥ 35 weeks of gestation after the first single blastocyst embryo transfer according to fresh or deferred-frozen transfer.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03349905, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.